# EDGAR Filing Document

**Accession Number:** 0001670690
**File Stem:** 0001127602-23-001274
**Filing Date:** 2023-1
**Character Count:** 10004
**Document Hash:** f0893c86bf827d90c75989c12a811ce3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001127602-23-001274.hdr.sgml**: 20230111

**ACCESSION NUMBER**: 0001127602-23-001274

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230109

**FILED AS OF DATE**: 20230111

**DATE AS OF CHANGE**: 20230111

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Chattopadhyay Sanat
- **CENTRAL INDEX KEY:** 0001670690

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-06571
- **FILM NUMBER:** 23523833

**MAIL ADDRESS:**
- **STREET 1:** 2000 GALLOPING HILL ROAD
- **CITY:** KENILWORTH
- **STATE:** NJ
- **ZIP:** 07033
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Merck & Co., Inc.
- **CENTRAL INDEX KEY:** 0000310158
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 221918501
- **STATE OF INCORPORATION:** NJ
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 2000 GALLOPING HILL ROAD
- **CITY:** KENILWORTH
- **STATE:** NJ
- **ZIP:** 07033
- **BUSINESS PHONE:** 908-740-4000

**MAIL ADDRESS:**
- **STREET 1:** 2000 GALLOPING HILL ROAD
- **CITY:** KENILWORTH
- **STATE:** NJ
- **ZIP:** 07033

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Merck & Co. Inc.
- **DATE OF NAME CHANGE:** 20091103

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SCHERING PLOUGH CORP
- **DATE OF NAME CHANGE:** 19920703

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Chattopadhyay Sanat<br><sub>(Last) (First) (Middle)</sub><br>MERCK & CO., INC.<br>126 EAST LINCOLN AVENUE<br><sub>(Street)</sub><br>RAHWAY, NJ 07065<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-01-09 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Exe V-P & Pres. MMD_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Merck & Co., Inc. [ MRK ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2023-01-09 |  | M |  | 83994 | A | $53.06 | 113494 | D |  |
| Common Stock | 2023-01-09 |  | S<sup>(1)</sup> |  | 35598 | D | 110.6146<sup>(2)</sup> | 77896 | D |  |
| Common Stock | 2023-01-09 |  | S<sup>(1)</sup> |  | 4538 | D | 111.7339<sup>(3)</sup> | 73358 | D |  |
| Common Stock | 2023-01-09 |  | S<sup>(1)</sup> |  | 3940 | D | 112.7823<sup>(4)</sup> | 69418 | D |  |
| Common Stock | 2023-01-09 |  | S<sup>(1)</sup> |  | 38216 | D | 113.7752<sup>(5)</sup> | 31202 | D |  |
| Common Stock | 2023-01-09 |  | S<sup>(1)</sup> |  | 1702 | D | 114.4612<sup>(6)</sup> | 29500 | D |  |
| Common Stock |  |  |  |  |  |  |  | 37873 | I | By GRAT 2021<sup>(7)</sup> |
| Common Stock |  |  |  |  |  |  |  | 45608 | I | By GRAT 2022<sup>(8)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | 53.06<sup>(9)</sup> | 2023-01-09 |  | M |  |  | 83994 | 2017-05-10<sup>(10)</sup> | 2026-05-09 | Common Stock | 83994 | $0 | 0 | D |  |

---

### Footnotes:

(1) The exercise and sale transactions reported in this Form 4 are made pursuant to Rule 10b5-1 trading plan.

(2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.2600 to $111.2000, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

(3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.2800 to $112.2100, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

(4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.3200 to $113.3100, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

(5) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.3500 to $114.3500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

(6) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.3700 to $114.5800, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

(7) The reporting person serves as the sole trustee of, and maintains complete investment control over, the Sanat Chattopadhyay 2021 Grantor Retained Annuity Trust.

(8) The reporting person serves as the sole trustee of, and maintains complete investment control over, the Sanat Chattopadhyay 2022 Grantor Retained Annuity Trust.

(9) Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

(10) The option became exercisable in equal installments on 5/10/2017, 5/10/2018 and 5/10/2019.

**Signature:** /s/ Kelly E. W. Grez as Attorney-in-Fact for Sanat Chattopadhyay  
**Date:** 2023-01-11

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**